Heart Beat: 03/08

A study published in the Jan. 18 issue of The Lancet showed that by intentionally damaging some red blood cells in a patient with systolic heart failure, doctors can "trick" the patients body into producing anti-inflammatory cells that help heal the damaged heart. Immune modulation therapy (IMT) was developed after it was determined that a heart failure patients natural immune response can sometimes produce high levels of inflammatory proteins and peptides called cytokines, which can actually damage the heart. In smaller amounts, cytokines can be protective. IMT research showed a 26 percent reduction in the risk for death and rehospitalization for heart failure patients with no heart attack history and 39 percent for patients classified with Stage 2 heart failure-systolic heart failure without symptoms such as shortness of breath, fatigue and reduced exercise intolerance.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access